NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Rosen Law Firm, a
global investor rights law firm, reminds purchasers of Ligand
Pharmaceuticals Incorporated securities (NASDAQ: LGND) of the
important January 17, 2017 lead
plaintiff deadline in the class action filed by the firm. The
lawsuit seeks to recover damages for Ligand investors under the
federal securities laws.
To join the Ligand class action, go to
http://www.rosenlegal.com/cases-996.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or
email pkim@rosenlegal.com or kchan@rosenlegal.com for information
on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A
CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO
NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants
made false and/or misleading statements and/or failed to disclose
that: (1) Ligand overstated the value of certain Deferred Tax
Assets by approximately $27.5 million
or 13%; (2) Ligand's outstanding convertible senior unsecured notes
due 2019 should have been classified as short-term debt rather than
long-term debt as of December 31,
2015; (3) Ligand did not maintain effective controls over
the accuracy and presentation of the accounting for income taxes
related to complex transactions; (4) in turn, Ligand lacked
effective internal control over financial reporting; and (5) as a
result, Defendants' statements about Ligand's business, operations
and prospects were materially false and misleading and/or lacked a
reasonable basis at all relevant times. When the true details
entered the market, the lawsuit claims that investors suffered
damages.
A class action lawsuit has already been filed. If you wish to
serve as lead plaintiff, you must move the Court no later than
January 17, 2017. If you wish to join
the litigation, go to http://www.rosenlegal.com/cases-996.html or
to discuss your rights or interests regarding this class action,
please contact Phillip Kim or
Kevin Chan of Rosen Law Firm toll
free at 866-767-3653 or via email at pkim@rosenlegal.com or
kchan@rosenlegal.com. Attorney Advertising. Prior
results do not guarantee a similar outcome.
Follow us for updates on LinkedIn:
https://www.linkedin.com/company/the-rosen-law-firm or on Twitter:
https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
Logo - http://photos.prnewswire.com/prnh/20160907/405060LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lgnd-loss-alert-rosen-law-firm-reminds-ligand-pharmaceuticals-incorporated-investors-of-important-deadline-in-class-action-filed-by-firm--lgnd-300367567.html
SOURCE Rosen Law Firm, P.A.